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Abstract
Aim: To investigate the role of bone morphogenetic protein 2 (BMP-2) in regulation of phosphatase and tensin homologue
deleted on chromosome ten (PTEN) and apoptosis of pulmonary artery smooth muscle cells (PASMCs) under hypoxia.
Methods: Normal human PASMCs were cultured in growth medium (GM) and treated with BMP-2 from 5–80 ng/ml under
hypoxia (5% CO2+94% N2+1% O2) for 72 hours. Gene expression of PTEN, AKT-1 and AKT-2 were determined by quantitative
RT-PCR (QRT-PCR). Protein expression levels of PTEN, AKT and phosph-AKT (pAKT) were determined. Apoptosis of PASMCs
were determined by measuring activities of caspases-3, -8 and -9. siRNA-smad-4, bpV(HOpic) (PTEN inhibitor) and GW9662
(PPARc antagonist) were used to determine the signalling pathways.
Results: Proliferation of PASMCs showed dose dependence of BMP-2, the lowest proliferation rate was achieved at 60 ng/ml
concentration under hypoxia (82.262.8%). BMP-2 increased PTEN gene expression level, while AKT-1 and AKT-2 did not
change. Consistently, the PTEN protein expression also showed dose dependence of BMP-2. AKT activity significantly
reduced in BMP-2 treated PASMCs. Increased activities of caspase-3, -8 and -9 of PASMCs were found after cultured with
BMP-2. PTEN expression remained unchanged when Smad-4 expression was inhibited by siRNA-Smad-4. bpV(HOpic) and
GW9662 (PPARc inhibitor) inhibited PTEN protein expression and recovered PASMCs proliferation rate.
Conclusion: BMP-2 increased PTEN expression under hypoxia in a dose dependent pattern. BMP-2 reduced AKT activity and
increased caspase activity of PASMCs under hypoxia. The increased PTEN expression may be mediated through PPARc
signalling pathway, instead of BMP/Smad signalling pathway.
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Introduction
Hypoxic pulmonary hypertension, one of the most common
pulmonary arterial hypertension, is characterized by increased
proliferation and reduced apoptosis of smooth muscle cells [1]. It
contributes to increased pulmonary vascular resistance and
increased pulmonary artery pressure. It leads to severe chronic
obstructive pulmonary disease and right ventricular failure [2].
Since the proliferation of pulmonary artery smooth muscle cells
(PASMCs) is an essential feature of vascular proliferative disorders,
considerable effort has been made to develop therapeutic strategies
to effectively suppress smooth muscle cells (SMCs) proliferation.
Bone morphogenetic protein 2 (BMP-2), which belongs to the
transforming growth factor beta super-family, is a negative
regulator of PASMC growth [3]. It is a potent inhibitor of
vascular SMCs proliferation both in vitro and in vivo [3]. BMP-2
has a potent inhibitory action on the growth of cultured rat aortic
SMCs. In addition, transfer BMP-2 gene into an injured artery
inhibited SMC proliferation in vivo as well as in vitro, using a rat
carotid balloon injury model. Wong et al., [4] demonstrated that
BMP-2 could inhibit PDGF-stimulated proliferation of arterial
SMCs through induction of p21. Hansmann et al., [5] shows that
anti-proliferative effects of BMP-2/BMP-RII signaling in primary
PASMCs can be attributed to activation of PPARc and its putative
transcription target apoE.
It has been shown that PPARc agonist up-regulated phospha-
tase and tensin homologue deleted on chromosome ten (PTEN)
expression in allergen-induced asthmatic lungs [6]. Zhang et al.,
[7] demonstrated that PPAR activator rosiglitazone inhibited hu-
man hepatocarcinoma BEL-7404 cell migration via up-regulating
PTEN. The tumour suppressor gene PTEN encodes a dual-
specificity phosphatase that recognizes protein and phosphatidy-
linositiol substrates and modulates cellular functions such as
migration and proliferation.
Though BMP-2 activates PPARc to achieve anti-proliferative
effects on SMCs, its role in regulation of PTEN expression in SMC
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increased PTEN expression of PASMCs under hypoxia in a dose
dependent pattern. BMP-2 reduced AKT activity and increased
caspase activity of PASMCs under hypoxia. The increased PTEN
expression may be mediated through PPARc signalling pathway,
instead of BMP/Smad signalling pathway.
Materials and Methods
Cell Culture of PASMC
Human primary PASMC was purchased from ScienCell
Research Laboratories (CA, USA). PASMC was cultured and
expanded in SMC growth medium (GM): SMC basal medium
(BM) (ScienCell Research Laboratories, CA USA) supplemented
with SMC growth supplement (ScienCell Research Laboratories),
10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin.
PASMCs were regularly passaged every 4–5 days. BMP-2
(Miltenyi Biotec, Singapore) was supplemented in the cell culture
medium to determine its effect on PASMC proliferation.
bpV(HOpic)(Merck,Germany),aPTENinhibitor,andGW9662
(Sigma Aldrich, USA), an antagonist of PPARc, were used to
determine the possible signalling pathwaysmediated byBMP-2.
Hypoxia Treatment
PASMC were cultured in hypoxic condition to determine the
anti-proliferative effect of BMP-2 on PASMCs. Hypoxia was
created in an incubator: 5% CO2+94% N2+1% O2,3 7 uC.
PASMCs cultured in GM supplemented with BMP-2 were
cultured in hypoxia incubator for 72 hours. The supernatant and
cellswerecollectedforcytotoxic,geneandproteinexpressionstudies.
Quantitative RT-PCR (QRT-PCR) Analysis
PASMCs were analyzed by QRT-PCR to determine gene
expression after treated with BMP-2. Total RNA was isolated
using RNA Isolation Kit (QIAGEN, USA) according to the
manufacturer’s instructions [8]. DNase I (Fermentas, USA) was
used to remove DNA from total RNA. cDNA was synthesized
using MaximaH First Strand cDNA Synthesis Kit (Fermentas,
USA). To quantify gene expression, MaximaH SYBR Green
qPCR Master Mix (2X) (Fermentas, USA) was used. The QPCR
thermal cycling protocol for 40 cycles was programmed as
following: 1 cycle of initial denaturation for 10 min, then
denaturation at 95uC for 15 seconds, annealing for 30 seconds
and extension at 72uC for 30 seconds. The primers used in the
study were listed in Table 1.
Cell Proliferation
Cell proliferation rate of PASMCs was determined by
CyQUANTH Cell Proliferation Assay Kit (Invitrogen, USA).
Briefly, 1610
4 PASMC/well were seeded into 24-well plate and
cultured with BM for 24 hours. The cell culture medium was
changed to GM supplemented with BMP-2 for 72 hours in
incubator under hypoxia. After that, cell supernatant was
removed. Cells were washed with PBS and frozen at 280uC
freezer for at least 1 hour. Then each well was incubated with
200 ml CyQUANTH cell-lysis buffer containing DNase-free RNase
(1.35 U/ml) to eliminate the RNA component of the fluorescent
signal for 1 hour at room temperature. After that, 200 ml cell lysis
buffer containing 2X solution of CyQUANTH GR dye was added
into each sample for 10 min. The fluorescence intensity was
measured using a Tecan fluorescence microplate reader (Tecan
Infinite M200, LabX Canada) at an excitation wavelength of
480 nm and an emission wavelength of 520 nm.
Lactate Dehydrogenase (LDH) Release for Cyto-toxic
Determination
The cyto-toxicity of BMP-2 towards PASMCs was determined
using CytoTox-ONE
TM Homogeneous Membrane Integrity
Assay (Promega, USA). Briefly, 5610
4 PASMCs/well were seeded
into 12-well plate in GM supplemented with BMP-2 for 72 hours
in incubator at 37uC. After that, cell culture supernatant was
collected and mixed with CytoTox-ONE
TM Reagent for at least
10 min. After addition of 50 ml stop solution, the fluorescence
signal was measured at an excitation wavelength of 560 nm and
an emission wavelength of 590 nm.
Western Blot Analysis of PASMCs
Protein expression levels from treated and non-treated PASMCs
were determined by western blot analysis [9]. PASMCs were
lysated with PhosphoSafe
TM Extraction Reagent (Merck, Ger-
many) and protein concentration was determined using Bradford
reagent (Bio-Rad Laboratories, USA). Proteins were separated and
transferred to nitrocellulose membrane. After washing with
10 mM Tris/HCl wash buffer (pH 7.6) containing 0.05%
Tween-20, the membrane was blocked with blocking buffer (5%
non-fat dry milk, 10 mM Tris pH 7.5, 100 mM NaCl, 0.1%
Tween-20) for 1 hour at room temperature. After blocking, the
membrane was incubated with 1:200–1:1,000 dilution of AKT,
phosphorylated (Ser 473) AKT(pAKT), PTEN, Smad-4, and
GAPDH (all purchased from Santa Cruz, USA) for overnight at
4uC. After that, anti-rabbit IgG conjugated with HRP (dilution:
1:3, 000 – 1:8,000) was used to detect the binding of antibodies.
The binding of the specific antibody was visualized using the
SuperSignal Chemiluminescent Substrate kit (Pierce, USA) and
exposed to X-ray film (Pierce, USA). The film was scanned and
the optical intensity of the band was quantified by Olympus Micro
Image software. The concentration of each protein sample was
expressed as percentage after normalizing to GAPDH (regarded as
100%).
Apoptosis Assays
Proteins from treated and non-treated PASMC were used to
determine the apoptosis of PASMCs by determining the activities
of caspase -3, -8 and -9.
Table 1. RT-PCR primers and annealing temperature.
GAPDH
606C, 90 bp, forward 5’ AGCCACATCGCTCAGACAC 3’
reverse 5’ TAAAAGCAGCCCTGGTGAC 3’
PTEN
60uC, 155 bp
forward 5’ TCACCAACTGAAGTGGCTAAAGA 3’
reverse 5’ CTCCATTCCCCTAACCCGA 3’
AKT-1
58uC, 125 bp
forward 5’ TAACCTTTCCGCTGTCGC 3’
reverse 5’ ATGTTGTAAAAAAACGCCG 3’
AKT-2
58uC, 127 bp
forward 5’ GGTCGCCAACAGCCTCAA 3’
reverse 5’ CACTTTAGCCCGTGCCTTG 3’
Smad-4
60uC, 128 bp
forward 5’ CTTCAGGGGCTTCTAAAACAG 3’
reverse 5’ TATCAGAGAGGGAAGAGACCAG 3’
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-8 Assay Kits, Fluorimetric (Sigma Aldrich, CASP3F and
CASP8F). The fluorescence intensity of caspase-3 was recorded
at wavelength of 360 nm for excitation, and at wavelength of
460 nm for emission, while it was 360 nm of excitation, and
440 nm of emission for caspase-8. The activity of caspase was
calculated as Fluorescence intensity (FI)/min/ml=DFlt/(t x v),
where DFlt=difference in fluorescence intensity between time
zero and time t minutes, t=reaction time in min, and v=volume
of sample in ml.
Similarly, Caspase-9 activity was determined by Caspase 9
Assay Kit, Fluorimetric (EMD4Biosciences, QIA72). The fluores-
cence intensity was recorded at wavelength 400 nm of excitation,
and wavelength 505 nm of emission. The same formula as the one
used for calculation of caspase-3 activity was used to calculate
caspase-9 activity.
Transfection of PASMC Using Lipoplexes Carrying pEGFP
or siRNA-Smad-4
Trypsinized PASMCs were seeded at a density of 1610
5cells/
well in 12-well plates and cultured with SMC growth medium
without antibiotics. A plasmid carrying enhanced green fluores-
cent protein (pEGFP) was used to transfect PASMCs to optimize
the transfection condition [8,10]. After optimization, pEGFP was
replaced with a plasmid carrying siRNA-Smad-4 (Invitrogen,
USA) to inhibit the Smad-4 gene expression, or a negative control
siRNA (siRNA-control, Invitrogen, USA).
The lipoplexes were manufactured by mixing lipofectamine-
2000 (Lipo) (Invitrogen, USA) with pEGFP (2 ug) from 1:1 to 4:1
(volume/weight: ul/ug). Lipofectamine and plasmid DNA were
diluted in 50 ml Opti-MEMH I Reduced Serum Medium
(Invitrogen, USA). The pEGFP lipoplexes were developed by
mixing the respective solutions. After mixing, the mixture was
vortexed for 10 seconds followed by centrifuge at lowest speed for
10 minutes. Then lipoplex mixture was sedated for 10 min at
room temperature and added into cell culture medium (SMC
growth medium without antibiotics) to transfect PASMCs for 24
hours at 37uC in incubator.
siRNA-Smad-4 or siRNA-control lipoplexes were developed by
replacing pEGFP with plasmid siRNA-Smad-4 or siRNA-control.
The volume of lipofectamine used would be the one that resulted
in the highest EGFP gene transfection efficiency. Next, lipofecta-
mine volume was fixed and siRNA concentration was adjusted
fom 40 nM up to 200 nM to identify the optimal ratio between
lipofectamine and siRNA-Smad-4 to inhibit Smad-4 gene
expression.
Statistic Analysis
All statistical analyses were performed using SPSS (version
10.0). The data were presented as mean6 standard error means
(SEM) and analyzed by the method of analysis of variance
(ANOVA) using Bonferroni test. All tests were performed with a
significance level of 5%.
Figure 1. Reduced PASMCs proliferation rate as a function of BMP-2 concentration when cultured in GM under hypoxia (A). PASMCs
cultured in GM supplemented with 0–80 ng/ml BMP-2. BMP-2 at the concentrations of 40 and 60 ng/ml significantly inhibited PASMC proliferation as
compared with GM without BMP-2. Typical pictures of PASMCs cultured in GM only (B), or GM supplemented with BMP-2 at 40 ng/ml (C). (*: vs 0 ng/
ml only, p,0.05) (Magnification=1006).
doi:10.1371/journal.pone.0035283.g001
Role of BMP-2 in PASMC under Hypoxia
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e35283Results
Dose Dependent Effects of BMP-2 on PASMC
Proliferation
The proliferative rate of PASMCs showed dose dependence of
BMP-2 when PASMCs was cultured under hypoxia
(Figure 1A&B). The number of PASMCs treated with 5 ng/ml
BMP-2 was reduced to 90.861% of non-treated PASMCs
(regarded as 100%), while they were 92.961.8% with 10 ng/ml,
88.461.2% with 20 ng/ml, 84.162.8% with 40 ng/ml,
82.262.8% with 60 ng/ml, 86.661% with 80 ng/ml. The
proliferation of PASMCs was significantly reduced at 40 and
60 ng/ml concentrations of BMP-2 compared with that cultured
in GM medium only.
Toxicity of BMP-2 Towards PASMCs
The toxicity of BMP-2 towards PASMCs was determined by
measuring LDH in the cell culture supernatant. No significant cell
injury was found when BMP-2 was increased up to 60 ng/ml
(Figure 2).
The percentage of LDH in supernatant was 2.360.6% when
PASMCs were cultured in GM without BMP-2. They were
2.760.4% with 5 ng/ml BMP-2, 260.4% with 10 ng/ml,
160.3% with 20 ng/ml, 160.2% with 40 ng/ml, 260.8% with
60 ng/ml. However, the leakage of LDH increased to 4.260.6%
when BMP-2 was 80 ng/ml concentration, which was significantly
increased as compared with that cultured in GM medium only
(Figure 2).
BMP-2 Significantly Increased PTEN Gene Expression
BMP-2 significantly increased PTEN gene expression at 8 hours
(2.460.2 folds, p,0.05) compared to any other time point
(Figure 3). Though it reduced at 24 hours (1.760.02 folds), it
was still significantly higher than those at baseline, 1 and 4 hours
after treatment (Figure 3).
BMP-2 did not Significantly Change AKT-1 and AKT-2
Gene Expression
Generally, no significant reduction or increment of AKT-1 gene
expression was found after addition of BMP-2 (Figure 4A). A
similar pattern was also found in AKT-2 gene expression. The
highest gene expression of AKT-2 was found at 24 hours
(1.460.22 folds) as compared with baseline. However, no
significant change was found after addition of BMP-2 (Figure 4B).
Western Blot Analysis of PASMCs Cultured in GM
Supplemented with BMP-2
Western blot analysis suggested that PTEN protein expression
level was BMP-2 dose dependent (Figure 5A). It was found that the
highest PTEN protein expression level was achieved when BMP-2
was between 40–60 ng/ml concentrations when PASMCs were
cultured in GM supplemented with BMP-2 for 8 hours
(Figure 5A&B).
Next, PASMCs were cultured in GM supplemented with
40 ng/ml BMP-2 for a serial time (Figure 5C&D). PTEN protein
expression level significantly increased between 4–8 hours in
presence of BMP-2 (Figure 5C&D). Reduction of pAKT was
found after addition of BMP-2 (Figure 5C&E). AKT protein
expression was unchanged in presence of BMP-2.
To determine whether PTEN inhibitor or PPARc antagonist
will inhibit or block the effect of BMP-2 on PTEN production,
PASMCs were pre-treated with 2.5 uM bpV (HOpic) (PTEN
inhibitor) or 1 uM GW9662 (PPARc antagonist) for 1 hour before
addition of BMP-2. It was found that bpV (HOpic) and GW9662
reduced PTEN protein expression (Figure 5F-I).
QRT-PCR and Western Blot Analysis for Smad-4 Gene and
Protein Expression
To determine whether BMP-2 mediated PTEN up-regulation
was mediated by Smad signalling pathway, a plasmid carrying
siRNA-Smad-4 was used to inhibit Smad-4 gene expression.
Lipofectamine-2000 was used as a transfection vehicle to
encapsulate siRNA-Smad-4 plasmid (Lipo-siRNA-Smad-4).
The transfection condition was first optimized using a plasmid
carrying enhance green fluorescent protein (pEGFP). Lipo-pEGFP
was added into cell culture medium for 24 hours. Then gene
transfection efficiency was determined (Figure 6). It was found that
the highest gene transfection and expression efficiency was
achieved when 6 ml Lipofectamine-2000 was used to carry 2 mg
pEGFP (V/W=3:1) to transfect 1610
5 trypsinized PASMCs.
Typical EGFP gene expression pictures of PASMCs after
transfection with Lipo-pEGFP were shown in Figure 6.
Figure 2. Toxicity of BMP-2 towards PASMCs when PASMCs were cultured in GM supplemented with 0280 ng/ml BMP-2 under
normoxia. It appears that only at 80 ng/ml concentration of BMP-2 resulted in significantly increased LDH leakage as compared with GM with 0 ng/
ml BMP-2. The percentage of LDH leakage was normalized to fresh GM (consider as 0%). (*: vs 0 ng/ml, p,0.05).
doi:10.1371/journal.pone.0035283.g002
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transfected with lipo-siRNA-Smad-4. QRT-PCR for Smad-4 gene
expression demonstrated that Smad-4 gene expression was
successfully reduced to 25% of non-transfected cells when 6 ml
Lipofectamine-2000 was used to carry 120 nM siRNA-Smad-4
(Figure 7A). This was confirmed by Western blot analysis showing
that Smad-4 protein expression level was significantly reduced
after siRNA-Smad-4 gene transfection (Figure 7B).
It was found that BMP-2 induced up-regulation of PTEN
protein expression was not abolished even when Smad-4 protein
expression was significantly reduced (Figure 7B-C). BMP-2 still
significantly reduced pAKT protein level when Smad-4 was
significantly reduced. (Figure 7D). This suggests that the up-
regulated PTEN protein expression by BMP-2 was not mediated
by Smad-4 signalling pathway.
Figure 3. Addition of BMP-2 (40 ng/ml) in GM increased PTEN gene expression of PASMCs. BMP-2 significantly increased PTEN
expression at 8 and 24 hours after treatment. (&: vs any other time point, p,0.05; *: vs 0, 1, and 4 hours, p,0.05).
doi:10.1371/journal.pone.0035283.g003
Figure 4. Addition of BMP-2 (40 ng/ml) in GM did not significantly change AKT-1 and AKT-2 gene expressions of PASMCs. No
significant reduction or increment of AKT-1 gene expression was found when PASMCs were cultured in GM supplemented with BMP-2 (A). Similarly,
no significant change of AKT-2 gene expression was found when PASMCs were cultured in GM supplemented with BMP-2 (B).
doi:10.1371/journal.pone.0035283.g004
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of PASMC
To determine whether PTEN inhibitor could reverse the anti-
proliferative effect of BMP-2 on PASMC, bpV (HOpic) was
included in cell culture medium for 72 hours under hypoxia
(Figure 8). It was found that addition of bpV(HOpic) recovered
PASMCs proliferation rate, suggesting it abolished the anti-
proliferative effect of BMP-2 on PASMCs. Combining the results
of western blot, these suggest that BMP-2 up-regulated PTEN
expression, which could be reversed by PTEN inhibitor.
GW9662 was also included in cell culture medium to investigate
whether the up-regulated PTEN was through PPARc signalling
pathway (Figure 8). It was found that GW9662 reversed the anti-
proliferative effect of BMP-2 on PASMCs. Combining with
western blot results, these suggest that BMP-2 could up-regulate
PTEN expression, which is through BMP-2/PPARc signalling
pathways.
BMP-2 Increased Caspase -3, -8, and -9 Activities
Significantly increased caspase-3 activity was found when
PASMCs were cultured in medium (6.560.18 FI/min/ml) sup-
plemented with BMP-2 for 8 hours (Figure 9A). Similarly,
significantly increased caspase-8 activity was also found when
PASMCs were cultured medium (6.160.3 FI/min/ml) supple-
mented with BMP-2 for 8 hours (Figure 9B).
Significantly increased caspase-9 activity was found when
PASMCs were cultured in medium (5.960.17 FI/min/ml) sup-
plemented with BMP-2 for 8 hours (Figure 9C).
These suggested that BMP-2 increased caspase activity and may
promote apoptosis of PASMC under hypoxia.
Discussion
The present study demonstrated that BMP-2 up-regulated
PTEN gene and protein expression levels of PASMCs under
hypoxia. BMP-2 increased caspase activities of PASMCs under
hypoxia. The increased PTEN expression was mediated through
BMP-2/PPARc signalling pathway.
The pulmonary vascular remodelling in pulmonary arterial
hypertension is characterized by changes in pulmonary vascular
structure [1,2]. This is partially caused by the imbalanced PASMC
proliferation and apoptosis [11]. Increased proliferation and
decreased apoptosis of PASMC results in thickening of the
Figure 5. Western blot analysis of PASMCs cultured in GM supplemented with BMP-2 under hypoxia. (A) A dose dependent effect of
BMP-2 on PTEN protein expression when BMP-2 was supplemented up to 80 ng/ml in GM. (B) Quantification of PTEN protein expression when BMP-2
was increased from 0–80 ng/ml after normalized to GAPDH (consider as 100%). (C) Typical pictures of PTEN and pAKT protein expressions as a
function of time when BMP-2 was supplemented at 40 ng/ml in GM. Quantification of PTEN (D) and pAKT (E) protein expressions after normalized to
GAPDH (consider as 100%). Reduced PTEN protein expression was found when GW9662 was added alone (F) or combined with BMP-2 (G). Reduced
PTEN protein expression was also found when bpV (HOpic) was added alone (H) or combined with BMP-2 (I). (*: vs 0 ng/ml BMP-2, p,0.05; &: vs 0
hour, p,0.05).
doi:10.1371/journal.pone.0035283.g005
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vascular resistance, and pulmonary artery pressure [12].
BMP-2 has been shown to inhibit human aortic SMCs [13] and
rat vascular SMCs proliferation [3]. Morrell and colleagues [14]
demonstrated that BMP-2 at doses of 1–100 ng/ml inhibited [3H]
thymidine incorporation in PASMCs from normotensive and
secondary pulmonary hypertension patients cultured in media that
contained FBS. Our results are consistent with these findings.
BMP-2 of 40–60 ng/ml concentrations most efficiently inhibited
PASMC proliferation under hypoxia. It significantly reduced
PASMC proliferation rate under GM condition. The anti-
proliferative effect of BMP-2 could be related to its role in up-
regulating of PTEN and increasing caspase activity of PASMCs
under hypoxia.
BMP-2 can activate Smad signalling system through BMP
receptor-II (BMP-RII) [15]. To determine whether the up-
regulated PTEN expression could also be mediated by Smad
pathway, gene expression of Smad-4 was inhibited using siRNA-
Smad-4. Smad-4 is a universal co-factor for Smad -1, -2, -3, -5,
and -8. It was found that when the expression of Smad-4 was
inhibited, PTEN protein expression was still up-regulated. This
suggested that BMP-2 mediated up-regulation of PTEN expres-
sion was independent of Smad signalling pathway.
In the current study, BMP-2 up-regulated PTEN gene and
protein expression levels. The up-regulated PTEN expression can
be inhibited by PPARc antagonist suggesting the up-regulated
PTEN gene and protein expressions were mediated by PPARc
signalling. We propose here that BMP-2 mediated up-regulation of
PTEN of PASMC under hypoxia was through PPARc signalling.
Hassman et al., [5] demonstrated that anti-proliferative effect of
BMP-2 was BMP-RII, PPARc, and apoE dependent. Others
found that BMP-2 exposure can regulate PTEN protein levels by
decreasing PTEN’s association with the degradative pathway [16].
Teresi et al., [17] demonstrated that transcriptional activation of
PPARc by lovastatin or rosiglitazone could increase PTEN
expression. Our data, at least in part, is consistent with these
and supports that BMP-2 through PPARc signalling up-regulates
PTEN expression that play an important role in anti-proliferation
of PASMC.
Current study also suggested that BMP-2 could increase caspase
activity of PASMC under hypoxia. It is known that chronic
hypoxia can prolong the growth of human vascular SMC by
inducing telomerase activity and telomere stabilization [18].
Zhang et al., [19] showed that BMP-2 treatment increased
pulmonary vascular SMC apoptosis, by TUNEL assay, via
decreasing Bcl-2 mRNA and protein expression. Lagna et al.,
[20] demonstrated that BMP can activate apoptotic signalling
cascade via BMP receptor II. The current study is consistent with
these findings. It was found that BMP-2 increased activities of
caspases -3, -8 and -9. The increased caspase activity can induce
the apoptosis of PASMC under hypoxia.
In summary, the study highlights that BMP-2 can increase
PTEN expression under hypoxia in a dose dependent pattern.
BMP-2 can increase caspase activities of PASMC under hypoxia.
The increased PTEN expression may be mediated through
PPARc signalling pathway, instead of BMP/Smad signalling
pathway.
Figure 6. Typical pictures of EGFP expression from pEGFP lipoplexes transfected PASMC when the ratio between Lipofectamine-
2000 and plasmid DNA was at (A) 1:1, (B) 2:1, (C) 3:1 and (D) 4:1, when 2 mg plasmid DNA was used per 1610
5 cells.
(Magnification=406).
doi:10.1371/journal.pone.0035283.g006
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e35283Figure 7. Smad-4 gene and protein expressions of Lipo-siRNA-Smad-4 transfected PASMCs. (A) QRT-PCR demonstrated that the lowest
Smad-4 gene expression was achieved when 120 nM siRNA-Smad-4 was used to transfect 1610
5 PASMCs. (B) Abolishment of Smad-4 protein
expression did not affect PTEN protein expression. Qantification of PTEN (C) and pAKT (D) protein expression after normalized to GAPDH (consider as
100%). (E) A non-coding siRNA was used as a negative control to determine the specificity of siRNA-Smad-4 targeting. (Lipo=lipofetamine-2000. *: vs
lipo only, p,0.05; &: vs GM only, p,0.05).
doi:10.1371/journal.pone.0035283.g007
Figure 8. Growth profile of PASMCs cultured in GM supplemented with BMP-2, GW9662 (PPARc antagonist) or bpV(HOpic) (PTEN
inhibitor). PPARc antagonist and PTEN inhibitor were added into respective cell culture medium 1 hour before adding BMP-2 (40 ng/ml). (The
number of PASMCs after cultured in GM only was considered as 100%). (*: vs GM only) (Lipo=Lipofetamine 22000).
doi:10.1371/journal.pone.0035283.g008
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